Adult Dosing & Uses
Dosing Forms & Strengths
FluMist
(intranasal)
- 0.2mL (prefilled single use sprayer)
Contains the following 3 viral strains for 2011/2012 season
- A/California/7/2009 (H1N1)-like (same strain as was used for 2009 H1N1 monovalent vaccines)
- A/Perth/16/2009 (H3N2)-like
- B/Brisbane/60/2008-like
FluMist Quadrivalent
(intranasal)
- 0.2mL (prefilled single use sprayer)
Contains the following 4 viral strains for 2012/2013 season
- A/California/7/2009 (H1N1)-like (same strain as was used for 2009 H1N1 monovalent vaccines)
- A/Perth/16/2009 (H3N2)-like
- B/Yamagata/16/88
- B/Victoria/2/87
Prevention of influenza A & B infection
CDC's ACIP recommends that everyone 6 months of age and older receive an annual influenza vaccination
Age <50 years: 0.2 mL/dose (0.1 mL/nostril); 1 dose/season
Intranasal administration for age 50 years or older: Safety and efficacy not established
Additional Information
Current vaccination schedules available at www.cdc.gov/nip/publications
Other Indications & Uses
Prevention of influenza A and B infection for patients aged 2-49 years
Pediatric Dosing & Uses
Dosing Forms & Strengths
FluMist
(intranasal)
- 0.2mL (prefilled single use sprayer)
Contains the following 3 viral strains for 2011/2012 season
- A/California/7/2009 (H1N1)-like (same strain as was used for 2009 H1N1 monovalent vaccines)
- A/Perth/16/2009 (H3N2)-like
- B/Brisbane/60/2008-like
FluMist Quadrivalent
(intranasal)
- 0.2mL (prefilled single use sprayer)
Contains the following 4 viral strains for 2012-2013 season
- A/California/7/2009 (H1N1)-like (same strain as was used for 2009 H1N1 monovalent vaccines)
- A/Perth/16/2009 (H3N2)-like
- B/Yamagata/16/88
- B/Victoria/2/87
Prevention of influenza A & B infection
CDC's ACIP recommends that everyone 6 months of age and older receive an annual influenza vaccination
Intranasal administration <2 year: Safety and efficacy not established
2-8 years and not vaccinated prevoiusly with influenza vaccine: 0.2 mL/dose (0.1 mL in each nostril); give 2 doses each at least 1 month apart
2-8 years previously vaccinated with influenza vaccine: As in adults; 0.2 mL/dose (0.1 mL/nostril); 1 dose/season
>9 years: As in adults; 0.2 mL/dose (0.1 mL/nostril); 1 dose/season
Drug Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
>10%
Adults
- Runny nose (41-45%)
- Headache (41-45%)
- Sore throat (26-30%)
- Weakness (26-30%)
- Myalgia (16-20%)
- Cough (11-15%)
Children
- Runny nose/nasal congestion (46-50%)
- Cough (36-40%)
- Irritability (16-20%)
- Headache (16-20%)
1-10%
Adults
- Chills (6-10%)
- Nasal congestion (6-10%)
- Sinusitis (2-5%)
Contraindications & Cautions
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967
Contraindications
Hypersensitivity to eggs, sulfites
Do not admin. IV/IM
Children/adolescents receiving aspirin
History of Guillain-Barre
Patients <2 yr, > 49 yr
Asthma, reactive airway disease
Diabetes, renal dysfunction
Hemoglobinopathies
Immunodeficiency diseases
On immunosuppressants
Any chronic pulmonary/cardivascular disorder
Cautions
Administer 48 hr after cessation of antiviral reactions
Do not administer within 2 wk of inactivated vaccine or 4 week of live virus vaccine
Pregnancy & Lactation
Pregnancy Category: C
Live virus vaccine; indicated for nonpregnant adolescents and adults
Lactation: unknown; avoid intranasal live vaccine while breastfeeding newborn
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Pharmacology
Mechanism of Action
Vaccine; vaccines convey active immunity via stimulation of production of endogenously produced antibodies
